InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,584.54
(
0.00%
)
US TECH 100
19,692.40
(
0.08%
)
Dow Jones
39,753.75
(
0.00%
)
Brent Oil
85.46
(
0.41%
)
Bitcoin
57,388.77
(
0.07%
)
Post# of 252581
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

tinkershaw

Send PM Follow Ignore
Followers 13
Posts 325
Boards Moderated 0
Alias Born 01/15/2008

tinkershaw

Re: None

Tuesday, 01/11/2011 12:55:09 PM

Tuesday, January 11, 2011 12:55:09 PM

Post# of 252581
Bioisimilar phase IIs continue:

http://www.reuters.com/article/idUSLDE7090BP20110110?feedType=RSS&feedName=rbssHealthcareNews&rpc=43

It will be interesting to find out what biosimilars (bioidenticals), MNTA is pursuing. I found it interesting that Novartis is going it without MNTA technology, which you would think would practically insure the identity of the drug and thus the result of the clinical trials (even if one were going the similar route vs. the identical route, with clinical trials).

Tinker
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up